MARKERS OF ENDOTHELIAL DYSFUNCTION AS CRITERIA FOR DESTABILIZATION OF THE DISEASE COURSE IN PATIENTS WITH CORONARY ARTERY DISEASE

Authors:

Abstract:

To determine the presence and severity of vascular endothelial dysfunction in patients with coronary artery disease and the possibility of diagnosing exacerbation of the atherosclerotic process in such patients by determining markers of endothelial dysfunction, 173 patients with different variants of the disease were examined. It was found that patients with unstable coronary artery disease were characterized by a more pronounced impairment of vascular endothelial function, as evidenced by a significant increase in biochemical markers of endothelial dysfunction (ET-1, sVCAM, and PAPP-A) not only compared to the control group but also to the patients with stable coronary artery disease. Therefore, such markers can be considered criteria for destabilizing the atherosclerotic process. Based on determining the threshold values of endothelial dysfunction in patients with coronary artery disease, groups with definite and possible (“grey zone”) destabilization and without destabilization were identified. Values of ET- 1 ≥10.43 ng/mL, sVCAM ≥1320.0 ng/mL, and PAPP-A ≥10.10 mIU/L were the basis for including patients in the group of patients with a destabilization of the disease even in the absence of clinical manifestations.

Keywords:

coronary artery disease destabilization of the atherosclerotic process endothelial dysfunction endothelin-1 soluble vascular cell adhesion molecules vasodilation function of the endothelium

References:

1. Antomonov MYu. Matematicheskaya obrabotka i analiz meditsinskikh s biologicheskikh dannykh. Kyiv: Maliy druk; 2006. 558 s [in Russian].
2. Kovalenko VM, Kornatskyy VM, editors. Actualni problemy zdorovya ta minimizatsiya yikh v umovakh zbroynoho konfliktu v Ukrayini: posibnyk. Kyiv: State Institution “National Scientific Center “Instytut kardiolohiyi imeni akademika M.D.Strazheska”; 2018 [in Ukrainian].
3. Conover CA, Oxvig C. Papp-A: A promising therapeutic target for healthy longevity. Aging Cell. 2016;16(2):205–9. doi:10.1111/acel.12564
4. Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, et al. Endothelin. Pharmacological Reviews. 2016;68(2):357–418. DOI: https://doi.org/10.1124/pr.115.011833
5. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Simoons ML, Zeiher AM. CAPTURE Study Investigators. Pregnancy- associated plasma protein-A levels in patients with acute coronary syndromes. Journal of the American College of Cardiology. 2005;45(2):229–237. doi: 10.1016/j.jacc.2004.09.060
6. Hulok A, Ściborski K, Marczak J, Bańkowski T, Poręba R, Negrusz-Kawecka M. Soluble cell adhesion molecules – does estimating svcam-1 and sicam-1 concentration provide additional information about cardiovascular risk in patients with coronary artery disease? Advances in Clinical and Experimental Medicine. 2014;23(5):735–41. doi:10.17219/acem/37232
7. Jankowich M, Choudhary G. Endothelin-1 levels and cardiovascular events. Trends in Cardiovascular Medicine. 2020;30(1):1–8. doi: 10.1016/j.tcm.2019.01.007
8. Li Y, Meng X, Zhou C, Zhou X. Pregnancy-associated plasma protein A as a predictor of all-cause mortality and cardiovascular events in patients with chronic kidney disease: A meta-analysis of prospective studies. Archives of Medical Science. 2020;16(1):8–15. doi:10.5114/aoms.2020.91283
9. Omran F, Kyrou I, Osman F, Lim V, Randeva H, Chatha K. Cardiovascular biomarkers: Lessons of the past and prospects for the future. International Journal of Molecular Sciences. 2022;23(10):5680. doi: 10.3390/ijms23105680
10. Romanova V, Sierkova V, Kuzminova N. P885Levels of soluble vascular cell adhesion molecule-1 and pregnancy-associated plasma protein A as the criteria of coronary heart disease destabilization. European Heart Journal. 2017;38(suppl_1). doi:10.1093/eurheartj/ehx501.p885
11. Serkova VK, Pavlov SV, Romanava VA, Monastyrskiy YI, Ziepko SM, Kuzminova NV, et al. Medical expert system for assessment of coronary heart disease destabilization based on the analysis of the level of soluble vascular adhesion molecules. SPIE Proceedings. 2017; 10445:104453O-8. doi: 10.1117/12.2280984
12. Shaposhnyk OA, Prykhodko NP, Savchenko LV, Shevchenko TI, Sorokina SI, Yakymyshyna LI. Clinical and diagnostic aspects of managing patients with valvular heart disease. World of medicine and biology. 2022;2(80):178–183. doi: 10.26724/2079-8334-2022-2-80-178-183
13. Townsend N, Kazakiewicz D, Lucy Wright F, Timmis A, Huculeci R, et al. Epidemiology of Cardiovascular Disease in Europe. Nature Reviews Cardiology. 2021;19(2):133–43. doi: 10.1038/s41569-021-00607-3
14. Yu X-H, He L-H, Gao J-H, Zhang D-W, Zheng X-L, Tang C-K. Pregnancy-associated plasma protein-A in atherosclerosis: Molecular marker, mechanistic insight, and therapeutic target. Atherosclerosis. 2018; 278:250–8. doi: 10.1016/j.atherosclerosis.2018.10.004

Publication:

«World of Medicine and Biology» Vol. 19 No. 84 (2023) , с. 129-133
УДК 616.13-002:616.12-005.4-08

DOI:

https://doi.org/10.26724/2079-8334-2023-2-84-129-133